Zoetis Announces Pricing of $1.5 Billion of Senior Notes
August 13 2018 - 8:08PM
Business Wire
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to
sell $1.5 billion of senior notes, consisting of $300 million
aggregate principal amount of floating rate senior notes due 2021,
$300 million aggregate principal amount of 3.250% senior notes due
2021, $500 million aggregate principal amount of 3.900% senior
notes due 2028 and $400 million aggregate principal amount of
4.450% senior notes due 2048, in an underwritten public
offering.
Zoetis intends to use the net proceeds to repay $500 million
drawn under the 364-day revolving credit facility entered into on
July 27, 2018, repay $500 million issued under its commercial paper
program, and for general corporate purposes. The offering is
expected to close on August 20, 2018, subject to customary closing
conditions.
Barclays Capital Inc., Citigroup Global Markets Inc., J.P.
Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith
Incorporated and MUFG Securities Americas Inc. are acting as joint
book-running managers of the underwriters. The final prospectus
supplement and accompanying prospectus, when available, may be
accessed through the SEC’s website at www.sec.gov. Alternatively,
the issuer, the underwriters or any dealer participating in the
offering will arrange to send the prospectus and prospectus
supplement upon request by calling Barclays at 1-888-603-5847, BofA
Merrill Lynch at 1-800-294-1322, Citigroup at 1-800-831-9146, J.P.
Morgan at 212-834-4533 and MUFG at 1-877-649-6848.
These securities are offered pursuant to a registration
statement that has become effective under the Securities Act of
1933, as amended. These securities are only offered by means of the
prospectus supplement and prospectus relating to the offering. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any offer or
sale of these securities in any state or other jurisdiction, where
the offer, solicitation or sale of these securities would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Zoetis
Zoetis is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more
than 60 years of experience in animal health, Zoetis discovers,
develops, manufactures and markets veterinary vaccines and
medicines, complemented by diagnostic products, genetic tests,
biodevices and a range of services. Zoetis serves veterinarians,
livestock producers and people who raise and care for farm and
companion animals with sales of its products in more than 100
countries.
DISCLOSURE NOTICES
Forward-Looking
Statements: This press release contains forward-looking
statements, which reflect the current views of Zoetis with respect
to business plans or prospects, future operating or financial
performance, future guidance, future operating models, expectations
regarding products, future use of cash and dividend payments, risks
or expectations related to its indebtedness, tax rate and tax
regimes, changes in the tax regimes and laws in other
jurisdictions, and other future events. These statements are
not guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more
of these risks or uncertainties materialize, or if management's
underlying assumptions prove to be incorrect, actual results may
differ materially from those contemplated by a forward-looking
statement. Forward-looking statements speak only as of the date on
which they are made. Zoetis expressly disclaims any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can be
found in the prospectus supplement and accompanying prospectus
under the caption “Risk Factors” and in our Annual Report on Form
10-K for the fiscal year ended December 31, 2017, including in the
sections thereof captioned “Forward-Looking Statements and Factors
That May Affect Future Results” and “Item 1A. Risk Factors,” in our
Quarterly Reports on Form 10-Q and in our Current Reports on Form
8-K. These filings and subsequent filings are available online
at www.sec.gov, Zoetis’ website, or on request from
Zoetis.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180813005700/en/
ZoetisMedia:Bill Price, 1-973-443-2742
(o)william.price@zoetis.comorElinore White, 1-973-443-2835
(o)elinore.y.white@zoetis.comorInvestor:Steve Frank,
1-973-822-7141 (o)steve.frank@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024